Synonyms for metrorrhagia or Related words with metrorrhagia
Examples of "metrorrhagia"
It may represent a possible endocrine dysfunction, resulting in menorrhagia or
(metro = womb, -rrhagia = excessive flow) is uterine bleeding at irregular intervals, particularly between the expected menstrual periods.
Irregular menstruation is a menstrual disorder whose manifestations include irregular cycle lengths as well as
(vaginal bleeding between expected periods).
Menometrorrhagia is a condition in which prolonged or excessive uterine bleeding occurs irregularly and more frequently than normal. It is thus a combination of
The roots, seeds and flowers of the iris, are used as ingredients in herbal medicines. They have been used as tocolysis (also called anti-contraction medications or labor represents) and to treat fetal
Besides the aforementioned physiologic forms,
may also represent abnormal uterine bleeding and be a sign of an underlying disorder, such as hormone imbalance, endometriosis, uterine fibroids, uterine cancer, or vaginal cancer.
"Irregular menstruation" is where there is variation in menstrual cycle length of more than approximately eight days for a woman. The term "
" is often used for irregular menstruation that occurs between the expected menstrual periods.
Prophylaxis and control of haemorrhages from small blood vessels, neonatal intraventricular haemorrhage, capillary bleeding of different etiology, including: menorrhagia and
without organic pathology, after trans-urethral resection of the prostate, hematemesis, melena, hematuria, epistaxis; secondary bleeding due to thrombocytopenia or thrombocytopathia, hypocoagulation, prevention of periventricular hemorrhages in prematurely born children.
Breakthrough bleeding (BTB) is any of various forms of vaginal bleeding, usually referring to mid-cycle bleeding in users of combined oral contraceptives, as attributed to insufficient estrogens. It may also occur with other hormonal contraceptives. Sometimes, "breakthrough bleeding" is classified as "abnormal" and thereby as a form of
, and sometimes it is classified as "not abnormal".
Oil from the seeds has been used in the treatment of sores, scabies, wounds and rheumatism. It has been credited with benefits as a digestant, and to have antivenom, antimicrobial, anti-inflammatory, anti-pyretic and anti-helmintic activity. It has also been used in the treatment of fevers, itching, nausea, leprosy, skin disorders, erysipelas, bleeding piles,
, menorrhagia, excessive thirst, and sweating.
Most unusual bleeding or irregular bleeding (
) in premenopausal women is caused by changes in the hormonal balance of the body. These changes are not pathological. Exceptionally heavy bleeding during menstruation is termed "menorrhagia" or "hypermenorrhea", while light bleeding is called "hypomenorrhea". Women on hormonal contraceptives can experience breakthrough bleeding and/or withdrawal bleeding. Withdrawal bleeding occurs when a hormonal contraceptive or other hormonal intake is discontinued.
Very little flow (less than 10 ml) is called "hypomenorrhea". Regular cycles with intervals of 21 days or fewer are "polymenorrhea"; frequent but irregular menstruation is known as "
". Sudden heavy flows or amounts greater than 80 ml are termed "menorrhagia". Heavy menstruation that occurs frequently and irregularly is "menometrorrhagia". The term for cycles with intervals exceeding 35 days is "oligomenorrhea". Amenorrhea refers to more than three to six months without menses (while not being pregnant) during a woman's reproductive years.
Estrone has been proven to be a known carcinogen for human females. The Occupational Safety and Health Administration (OSHA) classifies estrone as an OSHA Select carcinogen. Exposure to estrone can cause breast tenderness or pain, cervical hyper secretion, menstrual disorders including menorrhagia and
, nausea, headache, hypertension, leg cramps, vision disturbances, and endometriosis pain in women. Mothers lactating can also experience a decrease in the production of breast milk. Estrone can be found in the urine of pregnant women and can also be excreted in feces. Estrone is commonly produced in large quantities of the livers of transgender women who take oral estradiol. This is a result of first pass metabolism converting estradiol to estrone.
Abnormal uterine bleeding is a general category that includes any bleeding from menstrual or nonmenstrual causes. Hypomenorrhea is abnormally light menstrual periods. Menorrhagia (meno = month, rrhagia = excessive flow/discharge) is an abnormally heavy and prolonged menstrual period.
is bleeding at irregular times, especially outside the expected intervals of the menstrual cycle. If there is excessive menstrual and uterine bleeding other than that caused by menstruation, menometrorrhagia (meno = prolonged, metro = uterine, rrhagia = excessive flow/discharge) may be diagnosed. Causes may be due to abnormal blood clotting, disruption of normal hormonal regulation of periods or disorders of the endometrial lining of the uterus. Depending upon the cause, it may be associated with abnormally painful periods.
In women, menstrual disturbances are common during spironolactone treatment, with 10 to 50% of women experiencing them at moderate doses and almost all experiencing them at a high doses. Most women taking moderate doses of spironolactone develop amenorrhea, and normal menstruation usually returns within two months of discontinuation. Spironolactone produces an irregular, anovulatory pattern of menstrual cycles. It is also associated with
and menorrhagia (or menometrorrhagia) in a large percentage of women. It has no birth control effect. It is thought that the weak progestogenic activity of spironolactnoe is responsible for these effects, although this has not been adequately evaluated nor firmly established. An alternative proposed cause is inhibition of 17α-hydroxylase and hence sex steroid metabolism by spironolactone and consequent changes in sex hormone levels.
MPA was independently discovered in 1956 by Syntex and the Upjohn Company. It was first introduced on 18 June 1959 by Upjohn in the United States under the brand name Provera (2.5, 5, and 10 mg tablets) for the treatment of amenorrhea,
, and recurrent miscarriage. An intramuscular formulation, Depo-Provera (400 mg/mL MPA), was also introduced in 1960 in the U.S. for the treatment of endometrial and renal cancer. MPA in combination with ethinylestradiol was introduced in 1964 by Upjohn in the U.S. under the brand name Provest (10 mg MPA and 50 μg ethinylestradiol tablets) as an oral contraceptive, but this formulation was discontinued in 1970. This formulation was marketed by Upjohn outside of the U.S. under the brand names Provestral and Provestrol, while Cyclo-Farlutal (or Ciclofarlutal) and Nogest-S were formulations available outside of the U.S. with a different dosage (5 mg MPA and 50 or 75 μg ethinylestradiol tablets). Upjohn also sought approval of intramuscular MPA as a long-acting contraceptive under the brand name Depo-Provera (150 mg/mL MPA) but the applications were rejected in 1967, 1978, and yet again in 1983. However, in 1992, the drug was finally approved by the FDA for this indication. A subcutaneous formulation was introduced in the U.S. under the brand name Depo-SubQ Provera 104 (104 mg/0.65 mL MPA) in December 2004 as a contraceptive, and subsequently was also approved for the treatment of endometriosis-related pelvic pain. MPA has also been marketed widely throughout the rest of the world as Provera and Depo-Provera as well as Farlutal, Perlutex, and Gestapuran, among many other brand names.
Copyright © 2017